Adynxx is set to gain a Nasdaq listing by merging with Alliqua BioMedical. The reverse merger comes six months after Adynxx committed to advancing pain drug brivoligide, despite the candidate coming up short in a midphase study.
San Francisco-based Adynxx funded the phase 2 trial of brivoligide in postsurgical pain patients with $16 million it raised in a series B round last year. Adynxx has backed away from plans to move the drug straight into phase 3 on the strength of the midphase data. But, with its current development plan centering on two midphase trials featuring a total of 260 patients, it will still need cash.
The merger with Alliqua gives Adynxx a route to investors. Having sold its wound care assets earlier this year, Alliqua has spent the past few months trying to offload anything else of value. Adynxx will take on the Nasdaq listing. A manufacturing facility, Alliqua’s last major asset, is up for sale.
If the deal closes as expected in the first quarter, the resulting company will look a lot like Adynxx. The West Coast biotech’s shareholders will own 86% of the combined company, which will be called Adynxx. Advancing brivoligide will be the top priority of the merged company.
The outstanding question is whether Adynxx can make a success of brivoligide. In phase 2, the EGR1 inhibitor was no better than placebo at reducing pain in the weeks after surgery. That resulted in the trial missing its primary endpoint, but Adynxx looked past the setback and instead focused on data from a subgroup of patients with higher scores on the pain catastrophizing scale (PCS).
Buoyed by the subgroup analysis, Adynxx plans to test brivoligide in patients who have a PCS score of 16 or higher following total knee arthroplasty or mastectomy.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
